Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Candesartan cilexetil/hydrochlorothiazide - Takeda

Drug Profile

Candesartan cilexetil/hydrochlorothiazide - Takeda

Alternative Names: Atacand HCT; Atacand Plus; Blopress Plus; CoKenzen; ECARD HD; ECARD LD; Parapres Plus 32; Parapres Plus Forte; TCV-116C

Latest Information Update: 26 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Developer AstraZeneca; Takeda
  • Class Antihypertensives; Benzimidazoles; Benzothiadiazines; Biphenyl compounds; Heart failure therapies; Tetrazoles
  • Mechanism of Action Angiotensin type 2 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 24 Jul 2018 Cheplapharm Arzneimittel acquires commercial rights to candesartan cilexetil/hydrochlorothiazide for Hypertension in Europe
  • 10 Dec 2012 Launched for Hypertension in Brazil (PO)
  • 10 Dec 2012 Launched for Hypertension in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top